Comparative effectiveness and safety of biological treatment options after tumour necrosis factor α inhibitor failure in rheumatoid arthritis: systematic review and indirect pairwise meta-analysis

Comparative effectiveness and safety of biological treatment options after tumour necrosis factor α inhibitor failure in rheumatoid arthritis: systematic review and indirect pairwise meta-analysis

Source :

• Annals of the Rheumatic Diseases [ 0003-4967 ] ; 2012-08.

Descripteurs français

• KwdFr :
  • Abatacept, Adulte d'âge moyen, Anticorps monoclonaux (usage thérapeutique), Anticorps monoclonaux d'origine murine (usage thérapeutique), Anticorps monoclonaux humanisés (usage thérapeutique), Antirhumatismaux (usage thérapeutique), Essais contrôlés randomisés comme sujet, Facteur de nécrose tumorale alpha (antagonistes et inhibiteurs), Femelle, Humains, Immunoconjugués (usage thérapeutique), Medline, Mâle, Rhumatisme articulaire aigu (traitement médicamenteux), Rituximab, Résultat thérapeutique, Substitution de médicament, Échec thérapeutique.
• MESH :
  • antagonistes et inhibiteurs : Facteur de nécrose tumorale alpha.
  • traitement médicamenteux : Rhumatisme articulaire aigu.
  • usage thérapeutique : Anticorps monoclonaux, Anticorps monoclonaux d'origine murine, Anticorps monoclonaux humanisés, Antirhumatismaux, Immunoconjugués.
• Pascal (Inist)
  • Anti-TNF-alpha, Antirhumatismal, Article synthèse, Chronique, Echec, Etude comparative, Polyarthrite rhumatoïde, Revue bibliographique, Rhumatologie, Toxicité, Traitement.
• MESH :
  • Abatacept, Adulte d'âge moyen, Essais contrôlés randomisés comme sujet, Femelle, Humains, Medline, Mâle, Rituximab, Résultat thérapeutique, Substitution de médicament, Échec thérapeutique.

English descriptors

• KwdEn :
  • Abatacept, Anti-Tumor Necrosis Factor-alpha, Antibodies, Monoclonal (therapeutic use), Antibodies, Monoclonal, Humanized (therapeutic use), Antibodies, Monoclonal, Murine-Derived (therapeutic use), Antirheumatic Agents (therapeutic use), Antirheumatic agent, Bibliographic review, Chronic, Comparative study, Drug Substitution, Failure, Female, Humans, Immunoconjugates (therapeutic use), MEDLINE, Male, Middle Aged, Randomized Controlled Trials as Topic, Review, Rheumatic Fever (drug therapy), Rheumatoid arthritis, Rheumatology, Rituximab, Toxicity, Treatment, Treatment Failure, Treatment Outcome, Tumor Necrosis Factor-alpha (antagonists & inhibitors).
• MESH :
  • chemical , antagonists & inhibitors : Tumor Necrosis Factor-alpha.
  • chemical , therapeutic use : Antibodies, Monoclonal, Antibodies, Monoclonal, Humanized, Antibodies, Monoclonal, Murine-Derived, Antirheumatic Agents, Immunoconjugates.
  • drug therapy : Rheumatic Fever.
• Teeft :
  • Abatacept, Adverse events, American college, Antirheumatic drugs, Arthritis, Arthritis rheum, Baseline, Baseline characteristics, Biological agents, Biological treatment options, Black line, Cochrane databases, Comparator drug, Control clin trials, Direct comparisons, Disease activity, Disease duration, Drug Substitution, Drug efficacy, Drug safety, Epidemiological research, Epidemiological research figure, Female, Golimumab, Hietzing hospital, Higher risk, Humans, Inadequate responders, Inadequate response, Indirect comparison, Indirect comparisons, Indirect pairwise comparisons, Infusion, Infusion reactions, Inhibitor, Internal medicine, Jadad score, Joint counts, MEDLINE, Male, Middle Aged, Necrosis, Other reasons, Pairwise, Pairwise comparisons, Patient characteristics, Placebo, Previous tnfi, Previous tnfi treatments, Primary analyses, Primary efficacy outcome, Primary outcome, Random effects model, Randomised, Randomized Controlled Trials as Topic, Rcts, Rescue treatment, Response rates, Rheum, Rheumatoid, Rheumatoid arthritis, Risk differences, Risk ratios, Rituximab, Safety outcomes, Sensitivity analyses, Serious infections, Significant improvement, Synthetic dmards, Systematic literature search, Systematic review, Systematic reviews, Time points, Tnfi, Tocilizumab, Treatment Failure, Treatment Outcome, Treatment arms, Trial populations, Tumour, Tumour necrosis factor inhibitors.

Abstract

• https://api.istex.fr/ark:/67375/NVC-L7B00QJH-D/fulltext.pdf

Affiliations:

• Autriche, États-Unis
• Massachusetts, Vienne (Autriche)
• Vienne (Autriche)

Links toward previous steps (curation, corpus...)

• to stream Istex, to step Corpus: 000833
• to stream Istex, to step Curation: 000833
• to stream Istex, to step Checkpoint: 000E90
• to stream PubMed, to step Corpus: 001912
• to stream PubMed, to step Curation: 001912
• to stream PubMed, to step Checkpoint: 001788
• to stream Ncbi, to step Merge: 000532
• to stream Ncbi, to step Curation: 000532
• to stream Ncbi, to step Checkpoint: 000532
• to stream Main, to step Merge: 003601
• to stream PascalFrancis, to step Corpus: 000089
• to stream PascalFrancis, to step Curation: 000175
• to stream PascalFrancis, to step Checkpoint: 000113
• to stream Main, to step Merge: 003879
• to stream Main, to step Curation: 003575

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/TocilizumabV1/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003575 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 003575 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    TocilizumabV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     ISTEX:63329160A1A21777E6FE3C67E6C822FAC87A0FA9
   |texte=   Comparative effectiveness and safety of biological treatment options after tumour necrosis factor α inhibitor failure in rheumatoid arthritis: systematic review and indirect pairwise meta-analysis
}}

This area was generated with Dilib version V0.6.34. Data generation: Fri May 22 09:34:00 2020. Site generation: Sun Mar 28 09:01:19 2021